Vorolanib

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Vorolanib is a drug with antiangiogenic and antineoplastic activities. In 2023, vorolanib was approved for use in China. It is used in combination with everolimus for the treatment of advanced renal cell carcinoma in patients who have previously received tyrosine kinase inhibitor treatment but failed. Vorolanib is also being evaluated for the treatment of neovascular age‑related macular degeneration. and its azidated and chlorinated version, termed EYE1118, is designed to be targeted to the eye by natural light to reduce retinal and choroidal neovascularization locally. It is a dual inhibitor that targets both vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs).

Vorolanib is a drug with antiangiogenic and antineoplastic activities. In 2023, vorolanib was approved for use in China. It is used in combination with everolimus for the treatment of advanced renal cell carcinoma in patients who have previously received tyrosine kinase inhibitor treatment but failed. Vorolanib is also being evaluated for the treatment of neovascular age‑related macular degeneration. and its azidated and chlorinated version, termed EYE1118, is designed to be targeted to the eye by natural light to reduce retinal and choroidal neovascularization locally. It is a dual inhibitor that targets both vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs).

Text derived from https://en.wikipedia.org/w/index.php?oldid=1355132632 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.